Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses (15-day Dosing) of BIIL 284 BS in Adult (300 mg) and Pediatric (150 mg) Cystic Fibrosis Patients

Safety, tolerability and pharmacokinetics following repeated doses (15-day dosing)

Study Overview

• Status: Completed
• Conditions: Cystic Fibrosis
• Intervention / Treatment: Drug: Placebo; Drug: BIIL 284 BS, high dose; Drug: BIIL 284 BS, low dose

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female ≥ 6 years (pediatric 6 - 17 years inclusive; adult ≥ 18 years); minimum weight requirement of 20 kg
• Confirmed diagnosis of CF (positive sweat chloride ≥ 60 milliequivalents (mEq)/liter (by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF phenotype
• Forced expiratory volume in one second (FEV1) > 25% predicted (using prediction equation's of Knudson et al)
• Clinically stable with no evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation within 2 weeks of screening
• Females of child bearing potential must have a negative pregnancy test at screening and, if sexually active, must be willing to use a double-barrier form of contraception for the duration of the study
• The patient or the patient's legally acceptable representative must be able to give informed consent in accordance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and local legislation
• The patient must be able to swallow the BIIL 284 tablet whole
• Patients taking a chronic medication must be willing to continue this therapy for the entire duration of the study

Exclusion Criteria:

• Patients with a history of allergy/hypersensitivity (including medication allergy) which is deemed relevant to the trial as judged by the Investigator
• Patients who have participated in another study with an investigational drug (including BI Trial 543.36) within one month or 6 half-lives (whichever is greater) preceding the screening visit
• Patients with known substance abuse, including alcohol or drug abuse, within 30 days prior to screening
• Female patients who are pregnant or lactating
• Patients who are unable to comply with breakfast requirements prior to dosing
• Patients who have received IV, oral or inhaled antibiotics or corticosteroids for a pulmonary exacerbation within 2 weeks of screening
• Patients who have started a new chronic medication for CF within 2 weeks of screening
• Patients with documented persistent colonization with B. cepacia (defined as more than one positive culture within the past year)
• Patients with clinically significant findings on chest x-ray which in the opinion of the Investigator precludes the patient's participation in the trial
• Patients with oxyhemoglobin saturation in room air < 90% by pulse oximetry
• Patients with hemoglobin < 9.0 g/dL; platelets < 100x10**9/L; prothrombin time (PT) > 1.5 times the upper limit of normal, serum glutamic-oxaloacetic transaminase (ALT) or serum glutamic-pyruvic transaminase (AST) > 2 times the upper limit of normal; creatinine > 1.8 mg/dL (adults) or > 1.4 mg/dL (pediatrics) at screening
• Clinically significant disease or medical condition other than CF or CF-related conditions that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. This includes significant hematological, hepatic, renal, cardiovascular, and neurologic disease. Patients with diabetes may participate if their disease is under good control prior to screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo
Experimental: BIIL 284 BS, low dose in pediatric patients	Drug: BIIL 284 BS, low dose
Experimental: BIIL 284 BS, high dose in adult patients	Drug: BIIL 284 BS, high dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes from baseline in physical examination		Pre-dose and 72 hours after last drug administration
Number of patients with clinically relevant findings in vital signs	blood pressure, pulse rate, respiratory rate, body temperature	Up to 72 hours after last drug administration
Number of patients with clinically relevant changes in spirometry		Pre-dose, up to 72 hours after last drug administration
Number of patients with clinically relevant changes in oximetry		Pre-dose, up to 72 hours after last drug administration
Number of patients with clinically relevant changes in 12-lead ECG		Pre-dose, up to 72 hours after last drug administration
Number of patients with clinically relevant findings in laboratory evaluation		Up to 72 hours after last drug administration
Number of patients with adverse events		Up to 72 hours after last drug administration

Secondary Outcome Measures

Outcome Measure	Time Frame
Area under the concentration-time curve of the analyte in plasma (AUC)	Up to 72 hours after last drug administration
Maximum measured concentration of the analyte in plasma (Cmax)	Up to 72 hours after last drug administration
Time from dosing to the maximum concentration of the analyte in plasma (tmax)	Up to 72 hours after last drug administration
Concentration of the analyte in plasma after 24 hours (C24h)	24 hours after drug administration
Pre-dose concentration of the analyte in plasma immediately before administration of the next dose (Cpre)	Up to day 16
Terminal rate constant of the analyte in plasma (λz)	Up to 72 hours after last drug administration
Terminal half-life of the analyte in plasma (t1/2)	Up to 72 hours after last drug administration
Mean residence time of the analyte in the body at steady state (MRTss)	Up to 72 hours after last drug administration
Apparent volume of distribution during the terminal phase λz following extravascular administration at steady state (Vz,ss/F)	Up to 72 hours after last drug administration
Accumulation ratio for AUC after the 15th dose over the dosing interval compared to the first dose (RA,AUC)	day 1, day 15
Accumulation ratio for Cmax after the 15th dose over the dosing interval compared to the first dose (RA,Cmax)	day 1, day 15

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start: April 1, 2002
• Primary Completion (Actual): November 1, 2002

Study Registration Dates

• First Submitted: October 16, 2014
• First Submitted That Met QC Criteria: October 20, 2014
• First Posted (Estimate): October 21, 2014

Study Record Updates

• Last Update Posted (Estimate): October 21, 2014
• Last Update Submitted That Met QC Criteria: October 20, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Cystic Fibrosis
• Other Study ID Numbers: 543.37